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Abstract
Exponential technologies double in power or processing speed every year, whereas their cost halves. Deception and
disruption are two key stages in the development of exponential technologies. Deception occurs when, after initial intro-
duction, technologies are dismissed as irrelevant, while they continue to progress, perhaps not as fast or with so many
immediate practical applications as initially thought. Twenty years after the first publications, clinical proteomics is still
not available in most hospitals and some clinicians have felt deception at unfulfilled promises. However, there are indica-
tions that clinical proteomics may be entering the disruptive phase, where, once refined, technologies disrupt established
industries or procedures. In this regard, recent manuscripts in CKJ illustrate how proteomics is entering the clinical realm,
with applications ranging from the identification of amyloid proteins in the pathology lab, to a new generation of urinary
biomarkers for chronic kidney disease (CKD) assessment and outcome prediction. Indeed, one such panel of urinary pepti-
domics biomarkers, CKD273, recently received a Food and Drug Administration letter of support, the first ever in the CKD
field. In addition, a must-read resource providing information on kidney disease-related proteomics and systems biology
databases and how to access and use them in clinical decision-making was also recently published in CKJ.
Exponential technologies double in power or processing speed
every year, whereas their cost halves [1]. The development of
exponential technologies follows well-characterized sequential
stages, including deception and disruption stages [2]. Deception
occurs when recently introduced technologies are dismissed as
irrelevant, while they continue to progress, perhaps not as fast
or with so many immediate practical applications as initially
thought. According to PubMed, initial references to proteomics
were published in 1997 and were hailed as presenting a rapidly
rising technology in the Post-Genomic Era [3]. By 1998,
proteomics had been used to study cyclosporine A nephrotoxic-
ity [4], and clinical proteomics was already a manuscript title in
2001 [5]. Fifteen years later, clinical proteomics is still not avail-
able in most hospitals. However, there are indications that clini-
cal proteomics may be entering the disruptive phase, where,
once refined, it may disrupt established industries or proce-
dures. In this regard, recent manuscripts in CKJ illustrate how
proteomics is entering the clinical realm, with applications
ranging from the identification of amyloid proteins in the path-
ology lab, to a new generation of urinary biomarkers for chronic
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kidney disease (CKD) assessment, and discuss available general
and kidney-specific systems biology databases [6–8].
Clinical proteomics represents one aspect of systems biol-
ogy. Papadopoulos et al. [6] provide guidance on systems biology
databases for use in kidney research. Systems biology refers to
diverse analysis techniques that are frequently referred to as -
‘omics’ and have in common the simultaneous assessment of
the expression or levels of multiple molecules, even thousands
of molecules, thus providing a systemic overview of biological
processes and requiring solid bioinformatics tools for data inter-
pretation. Systems biology approaches include genomics, epige-
nomics, transcriptomics, proteomics and its varieties (e.g.
phosphoproteomics) and metabolomics [9]. While for many
years, transcriptomics allowed the sensitive quantitative
assessment of gene expression, proteomics appeared to lag
behind. Against the backdrop of transcriptomics studies that
identified novel mediators of kidney injury among thousands of
differentially expressed genes within activated molecular path-
ways or novel biomarkers, such as neutrophil gelatinase-associ-
ated lipocalin (NGAL) [10], proteomics identified just a few high-
expression proteins. In any case, systems biology research has
generated huge amounts of data that are available to research-
ers as accessible databases. The review on existing databases in
the kidney disease context and how to access them by
Papadopoulos et al. [6] is a key resource and must-read manu-
script for any researcher interested in kidney physiology and
disease. Access to these databases allows later reanalysis from
a different perspective or after collating with a different set of
experiments or results. Moreover, multi-omics approaches
combining epigenetics, transcriptomics, proteomics and metab-
olomics databases will greatly improve our capacity to appre-
hend the complexity of physiology and disease. These
databases will be a key resource for clinicians in a new world of
personalized medicine, which needs to embrace complexity
and distill it into clinical decision-making. Most clinicians are
still unaware of the potential impact of these technologies in
the clinical setting within the near future. However, geneticists
and specialists in rare diseases are already using on a daily
basis population genetics databases in order to try to discern
between single-nucleotide polymorphisms, hypomorphic
genetic variants and disease-causing mutations [11–13]. Of the
different systems biology approaches, it is likely, as illustrated
below, that clinicians will become familiar with clinical proteo-
mics in the next few years.
Picken [7] discusses the clinical use of proteomics in the
pathology lab to identify the protein composition of amyloid
deposits. This takes advantage of mass spectrometry (MS)-
based proteomics and of the abundance of amyloid proteins in
tissue where, frequently, they are the dominant proteins.
Currently, at least 31 proteins may be deposited as amyloid, and
therapy is aetiology specific [7]. Thus, it is necessary to identify
the nature of amyloid deposits [14]. High-profile manuscripts
have illustrated the misdiagnosis of more rare variants as one
of the common [Amyloid A (AA) or Amyloid L (AL)] causes of
amyloidosis [15]. Furthermore, exome sequencing has also
drawn attention to the potential coexistence of two or more
genetic defects, which result in atypical clinical presentations
and non-Mendelian inheritance [16]. The current issue of CKJ
presents a renal biopsy where both leukocyte cell-derived che-
motaxin 2 (ALECT2) and AA amyloidosis were present in the
same patient, and resulted from a genetic predisposition [17]. In
this case, genetic analysis provided the clue, whereas a tradi-
tional approach, based on tissue immunofluorescence or immu-
nohistochemistry initially for the most common variants, may
have resulted in an incomplete diagnosis. The need to test mul-
tiple potential aetiologies requires time-consuming step-by-
step testing or expensive simultaneous testing of all the possi-
bilities. It is precisely the multidimensional nature of the diag-
nostic tests used that suits proteomics best [7]. In this regard,
ALECT2 amyloidosis, which is now recognized as one of the
most common causes of systemic amyloidosis in North
America, was identified through proteomics analysis [18]. In
2017, a proteomics analysis of a kidney biopsy identified for the
first time amyloid ApoCII (AApoCII) amyloidosis [19].
Finally, Pontillo and Mischak [8] discuss the urinary
peptidomics-based classifier CKD273. This classifier results
from capillary electrophoresis–mass spectrometry-based analy-
sis of 273 protein fragments in urine. Ever since its description
in 2010 [20], as a biomarker that allowed specific detection of
CKD among >600 patients and controls, evidence has accumu-
lated of its potential usefulness in patient care. In a large cohort
of 2672 CKD patients, CKD273 was a better predictor of CKD pro-
gression than urinary albumin in early CKD glomerular filtra-
tion rate (GFR) G categories [21]. Furthermore, CKD273 is
responsive to therapy with renin–angiotensin system blockers,
and a high CKD273 score was associated with a response to the
anti-albuminuric effect of spironolactone [22]. A recent system-
atic review concluded that by 2014, initial promising evidence
supported the utility of CKD273 in predicting CKD progression
[23]. CKD273 obtained high-evidence levels (score range 1b)
according to the Oxford Evidence-Based Medicine guideline,
supporting its utility for predicting CKD progression, whereas
lower scores (score ranges 1–4) were attained according to the
Strength of Recommendation Taxonomy guidelines [23]. The
evidence was derived from prospective cohort studies and dis-
closed that CKD273 performed independently of age and gen-
der, predicting the development of pathological albuminuria
categories A2 or A3 and fast CKD progression, defined as >5%
annual decrease in estimated GFR (eGFR). In June 2016, the US
Food and Drug Administration issued a biomarker letter of
support for the CKD273 classifier [24] meant to improve its visi-
bility and to encourage ‘the further development of CKD273 to
be used in combination with current measures (i.e., albuminu-
ria, serum creatinine) in early phase clinical trials in diabetic
kidney disease to identify patients with early stage disease who
may be more likely to progress’. CKD273 is now available as an
in vitro diagnostic device in Germany for the early detection of
CKD in diabetic patients, although only for privately insured
patients [8].
Further testing is ongoing. The precise role of CKD273 as a
tool in the patient risk stratification workup and therapeutic
decision-making is being explored in an ongoing European
Union-funded multicentric randomized clinical trial (PRIORITY)
[25]. PRIORITY addresses whether risk stratification of diabetic
patients with albuminuria category A1 based on the CKD273
classifier with subsequent therapeutic decision-making based
on CKD273-based risk stratification offers outcome advantages
in early diabetic kidney disease. Patients at high risk of progres-
sion, based on CKD273 results, were randomized to spironolac-
tone or placebo.
Thus, CKD273 may provide solutions for two unmet needs.
First, the development of novel surrogate endpoints that avoid
the current need to follow patients over many years and which
allow enriching population for accelerated progression of CKD
beyond currently available markers, urinary albumin:creatinine
ratio (UACR) and eGFR. Secondly, the need for new tools for the
earlier diagnosis of CKD. Current tools to diagnose CKD only
allow a late diagnosis of the condition (Figure 1), resulting in the
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existence of a blind spot for early-stage CKD: kidney injury is
present but we lack tools to identify and diagnose it. Thus,
physiological albuminuria in young healthy individuals is usu-
ally under 5 mg/g. However, UACR is allowed to increase 6-fold
to 30 mg/g before a diagnosis of CKD is entertained [26]. The
diagnosis may be even later when proteinuria is assessed, since
it may remain within normal limits when albuminuria is
already pathological; GFR criteria for the diagnosis of CKD also
allow for roughly 50% of renal function to be lost before a CKD
diagnosis is made. A clear illustration of the potential magni-
tude of the problem is provided by autosomal dominant poly-
cystic kidney disease (ADPKD). In this regard, the availability of
an early diagnosis technique, renal ultrasound, allows the diag-
nosis of CKD a full decade or more before UACR of eGFR become
pathological. However, this is only the tip of the iceberg, since
ADPKD kidneys are already abnormal at birth. Thus, the diagno-
sis of CKD may still be delayed, despite the use of imaging
techniques.
Clinical proteomics may contribute to close the blind spot in
the general CKD population, in the same manner as imaging
does in polycystic kidney disease. In this regard, the current 3D
initial approach to the patient with CKD (eGFR, albuminuria/pro-
teinuria and glomerular haematuria) may in the future be
replaced by a multidimensional systems biology approach (Figure
2). Further refinement may one day lead to the potential for non-
invasive diagnosis of aetiology [27] or, perhaps, more interest-
ingly, of a molecular pathophysiological pathways-based classifi-
cation that may help to choose a specific therapeutic approach,
effectively yielding a nephrological ‘liquid biopsy’ based on
assessment of urine, perhaps within a multi-omics systems biol-
ogy approach. In this regard, applying peptidomics technology
similar to CKD273, novel urinary peptides classifiers showed
good-to-excellent accuracy for discrimination of seven different
causes of CKD from one another (area under the receiver operat-
ing characteristic curve ranged from 0.77 to 0.95) and the compo-
nent peptides provided insights into pathophysiological
mechanisms [27]. The aetiologies tested encompassed major
causes of end-stage kidney disease, such as diabetic kidney dis-
ease, hypertensive nephrosclerosis, diverse primary glomerulo-
nephritides (primary focal segmental glomerulosclerosis, IgA
nephropathy, membranous nephropathy) and lupus nephritis.
In conclusion, a series of signals suggests that clinical pro-
teomics has entered the disruptive phase of exponential tech-
nologies and it is likely that it will be incorporated in routine

























Fig. 1. The CKD blind spot. (A) Car mirror blind spot. (B) CKD blind spot. The
most frequently used diagnostic and staging criteria for CKD, based on GFR and
UACR, are late events, allowing a blind spot that may last years, characterized
by progression of undiagnosed kidney injury. As is the case with driving, a blind
spot may be fatal, since specific therapy may be initiated too late to prevent the
need for renal replacement therapy or premature death. (C) Imaging addresses
the blind spot in ADPKD, allowing the diagnosis of CKD decades before GFR or
UACR values allow diagnosing CKD. A key research priority is the search for bio-
markers that allow closing the blind spot in other causes of CKD.
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Fig. 2. Clinical proteomics for assessment of CKD aetiology and major molecular
pathways involved. (A) Since the 1960s, the initial diagnostic approach to CKD
has been 3D, based on the assessment of a limited number of parameters
(mainly albuminuria/proteinuria, glomerular haematuria, GFR) that summarize,
in perhaps too simple a way, the interplay of diverse aetiologies and diverse
molecular pathways of kidney injury. The result has been a considerable delay
in the diagnosis of CKD and also in the development of novel therapeutic
approaches to kidney disease. (B) Systems biology and, specifically, clinical pro-
teomics allow the nephrologist to embrace complexity in order to develop per-
sonalized medicine approaches that provide information within a single
diagnostic test that leads to the diagnosis of CKD, to identification of aetiology
and molecular pathways (and, thus, of the most appropriate therapy) and out-
come prediction.
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biology-based approaches, within an integrated personalized
medicine framework. The availability and physician familiarity
with systems biology databases is a key step towards achieving
this goal.
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